CROSS COUNTRY HEALTHCARE INC – 10-K – Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of
operations should be read in conjunction with Item 1. Business, Item 1A. Risk
Factors, Forward-Looking Statements, and Item 15. Consolidated Financial
Statements and the accompanying notes and other data, all of which appear
elsewhere in this Annual Report on Form 10-K.

Management's Discussion and Analysis below generally discusses 2022 and 2021
items and year-to-year comparisons between 2022 and 2021. Discussions of 2020
items and year-to-year comparisons between 2021 and 2020 that are not included
in this Form 10-K can be found in "Management's Discussion and Analysis of
Financial Condition and Results of Operations" in the Company's Annual Report on
Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on
February 28, 2022 and such information is incorporated herein by reference.

Business Overview

We provide total talent management services, including strategic workforce
solutions, contingent staffing, permanent placement, and consultative services
for healthcare customers across the continuum of care, by recruiting and placing
highly qualified healthcare professionals in virtually every specialty and area
of expertise. In addition to clinical roles such as school nurses, speech
language, and behavioral therapists, we place non-clinical professionals such as
teachers, substitute teachers, and other education specialties at educational
facilities across the nation. Our diverse customer base includes both public and
private acute care and non-acute care hospitals, outpatient clinics, ambulatory
care facilities, single and multi-specialty physician practices, rehabilitation
facilities, PACE programs, urgent care centers, local and national healthcare
systems, managed care providers, public and charter schools, correctional
facilities, government facilities, pharmacies, and many other healthcare
providers. Through our national staffing teams, we offer our workforce solutions
and place clinicians on travel and per diem assignments, local short-term
contracts, and permanent positions. In addition, we continually evaluate
opportunities to acquire companies that would complement or enhance our
business, like Mint and HireUp.

Our workforce solutions include MSPs, RPO, project management, and other
outsourcing and consultative services as described in Item 1. Business in this
Annual Report on Form 10-K. By utilizing the solutions we offer, customers are
able to better plan their personnel needs, optimize their talent acquisition and
management processes, strategically flex and balance their workforce, have
access to quality healthcare personnel, and provide continuity of care for
improved patient outcomes. We have a history of investing in diversity,
equality, and inclusion as a key component of the organization's overall
corporate social
                                       24
--------------------------------------------------------------------------------

responsibility program, which we believe is closely aligned with our core values
to create a better future for our people, communities, and our stockholders.

The Company's two reportable segments offer services to its customers as
described below:

?  Nurse and Allied Staffing - For the year ended December 31, 2022, Nurse and
Allied Staffing represented approximately 96% of total revenue. The Nurse and
Allied Staffing segment provides workforce solutions and traditional staffing,
including temporary and permanent placement of travel nurses and allied
professionals, as well as per diem and contract nurses and allied personnel. We
also provide clinical and non-clinical professionals on short-term and long-term
assignments to customers such as local and national healthcare plans, managed
care providers, public and charter schools, correctional facilities, skilled
nursing facilities, and other non-acute settings. In addition, Nurse and Allied
Staffing provides retained search services for healthcare professionals, as well
as contingent search and recruitment process outsourcing services. We provide
flexible workforce solutions to our healthcare customers through diversified
offerings designed to meet their unique needs, including: MSP, RPO, and
consulting services.

?  Physician Staffing - For the year ended December 31, 2022, Physician Staffing
represented approximately 4% of total revenue. Physician Staffing provides
physicians in many specialties, as well as CRNAs, NPs, and PAs as independent
contractors on temporary assignments throughout the U.S.

Summary of Operations

For the year ended December 31, 2022, revenue from services increased 67%
year-over-year to $2.8 billion, due to strong performance in both our Nurse and
Allied Staffing and Physician Staffing segments, primarily driven by an increase
in volume growth and the number of professionals on assignment as a result of
our investment in people and technology. Net income attributable to common
stockholders for the year ended December 31, 2022 was $188.5 million, as
compared to $132.0 million for the year ended December 31, 2021.

In addition to our scheduled payments, on June 23, 2022 and October 26, 2022, we
made optional prepayments on our term loan of $50.0 million, totaling
$100.0 million, to reduce interest costs, and incurred prepayment premiums of
$1.0 million pursuant to the Term Loan Agreement.

On October 3, 2022, we entered into an asset purchase agreement with Mint
Medical Physician Staffing, LP and Lotus Medical Staffing LLC, which expanded
our locum tenens portfolio. On December 13, 2022, we entered into an asset
purchase agreement with HireUp Leadership, Inc., which strengthened our position
in the talent management landscape.

For the year ended December 31, 2022, cash flow provided by operating activities
was $134.1 million, with net borrowings of $67.6 million on our senior secured
asset-based credit facility (ABL), and an increase in working capital stemming
from an increase in accounts receivable partly offset by the timing of
disbursements. As of December 31, 2022, we had $3.6 million in cash and cash
equivalents and a principal balance of $73.9 million outstanding on our term
loan. Borrowing base availability under the ABL was $300.0 million, with $76.8
million of borrowings drawn under our ABL, and $18.2 million of undrawn letters
of credit outstanding, leaving $205.0 million of excess availability. See Note 8
- Debt to our consolidated financial statements.

See Results of Operations, Segment Results, and Liquidity and Capital Resources
sections that follow for further information.

Operating Metrics

We evaluate our financial condition by tracking operating metrics and financial
results specific to each of our segments. Key operating metrics include hours
worked, days filled, number of contract personnel on a full-time equivalent
(FTE) basis, revenue per FTE, and revenue per day filled. Other operating
metrics include number of open orders, candidate applications, contract
bookings, length of assignment, bill and pay rates, and renewal and fill rates,
number of active searches, and number of placements. These operating metrics are
representative of trends that assist management in evaluating business
performance. Due to the timing of our business process and other factors,
certain of these operating metrics may not necessarily correlate to the reported
U.S. GAAP results for the periods presented. Some of the segment financial
results analyzed include revenue, operating expenses, and contribution income.
In addition, we monitor cash flow, as well as operating and leverage ratios, to
help us assess our liquidity needs.

                                       25
--------------------------------------------------------------------------------

Business Segment                           Business Measurement
Nurse and Allied Staffing                  FTEs represent the average number of Nurse and
                                           Allied Staffing contract personnel on a full-time
                                           equivalent basis.
                                           Average revenue per FTE per day is calculated by
                                           dividing the Nurse and Allied Staffing revenue,
                                           excluding permanent placement, per FTE by the number
                                           of days worked in the respective periods.

Physician Staffing                         Days filled is calculated by dividing the total
                                           hours invoiced during
                                           the period, including an estimate for the impact of
                                           accrued revenue,
                                           by eight hours.
                                           Revenue per day filled is calculated by dividing
                                           revenue as reported
                                           by days filled for the period presented.


Results of Operations

The following table summarizes, for the periods indicated, selected consolidated
statements of operations and comprehensive income (loss) data expressed as
a percentage of revenue. Our historical results of operations are not
necessarily indicative of future operating results.

                                                        Year Ended December 31,
                                                           2022                2021
Revenue from services                                            100.0  %     100.0  %
Direct operating expenses                                         77.6         77.6
Selling, general and administrative expenses                      11.6         12.8
Bad debt expense                                                   0.3          0.3
Depreciation and amortization                                      0.5          0.6

Acquisition and integration-related costs                            -          0.1
Restructuring costs                                                0.1          0.2

Impairment charges                                                 0.2          0.1
Income from operations                                             9.7          8.3

Interest expense                                                   0.5          0.4

Loss on early extinguishment of debt                               0.1            -
Other income, net                                                    -         (0.1)
Income before income taxes                                         9.1          8.0
Income tax expense                                                 2.4          0.1

Net income attributable to common stockholders                     6.7  %       7.9  %



                                       26

--------------------------------------------------------------------------------

Comparison of Results for the Year Ended December 31, 2022 compared to the Year
Ended December 31, 2021

                                                                                  Year Ended December 31,
                                                                                                  Increase                Increase
                                                                                                 (Decrease)              (Decrease)
                                                          2022                 2021                   $                      %
                                                                                   (Amounts in thousands)
Revenue from services                                $ 2,806,609          $ 1,676,652          $  1,129,957                     67.4  %
Direct operating expenses                              2,178,923            1,301,653               877,270                     67.4  %
Selling, general and administrative expenses             324,209              215,292               108,917                     50.6  %
Bad debt expense                                           9,609                4,783                 4,826                    100.9  %
Depreciation and amortization                             12,576                9,852                 2,724                     27.6  %

Acquisition and integration-related costs                    726                1,068                  (342)                   (32.0) %
Restructuring costs                                        1,861                2,630                  (769)                   (29.2) %

Impairment charges                                         5,597                2,070                 3,527                    170.4  %
Income from operations                                   273,108              139,304               133,804                     96.1  %
Interest expense                                          14,391                6,866                 7,525                    109.6  %

Loss on early extinguishment of debt                       3,728                    -                 3,728                    100.0  %
Other income, net                                         (1,336)                (770)                 (566)                   (73.5) %
Income before income taxes                               256,325              133,208               123,117                     92.4  %
Income tax expense                                        67,864                1,206                66,658                          NM

Net income attributable to common stockholders $ 188,461 $

   132,002          $     56,459                     42.8  %



NM - Not meaningful

Revenue from services

Revenue from services increased $1.1 billion, or 67.4%, to $2.8 billion for the
year ended December 31, 2022, as compared to $1.7 billion for the year ended
December 31, 2021, due to strong performance in both our Nurse and Allied
Staffing and Physician Staffing segments, primarily driven by an increase in the
number of professionals on assignment, as well as higher bill rates in Nurse and
Allied. See further discussion in Segment Results.

Direct operating expenses

Direct operating expenses are comprised primarily of field employee compensation
and independent contractor expenses, housing expenses, travel expenses, and
related insurance expenses. Direct operating expenses increased $877.3 million,
or 67.4%, to $2.2 billion for the year ended December 31, 2022, as compared to
$1.3 billion for the year ended December 31, 2021, as a result of revenue
increases. As a percentage of total revenue, direct operating expenses were
77.6% for the years ended December 31, 2022 and 2021.
Selling, general and administrative expenses

Selling, general and administrative expenses increased $108.9 million, or 50.6%,
to $324.2 million for the year ended December 31, 2022, as compared to $215.3
million for the year ended December 31, 2021, primarily due to increases in
compensation and benefits, marketing and consulting expense, and computer
subscription fees. As a percentage of total revenue, selling, general and
administrative expenses decreased to 11.6% for the year ended December 31, 2022
as compared to 12.8% for the year ended December 31, 2021.

Bad Debt Expense

Bad debt expense for the year ended December 31, 2022 was $9.6 million as
compared to $4.8 million for the year ended December 31, 2021. The increase is
due primarily to higher receivables at year end with a 14 day increase in DSO
year over year. As a percentage of revenue, bad debt expense was 0.3% for the
years ended December 31, 2022 and 2021.

                                       27
--------------------------------------------------------------------------------

Depreciation and amortization expense

Depreciation and amortization expense for the year ended December 31, 2022 was
$12.6 million as compared to $9.9 million for the year ended December 31, 2021.
The increase is primarily due to the additional amortization of other intangible
assets from the WSG and Selected acquisitions. See Note 5 - Goodwill, Trade
Names, and Other Intangible Assets to our consolidated financial statements. As
a percentage of revenue, depreciation and amortization expense was 0.5% for the
year ended December 31, 2022 and 0.6% for the year ended December 31, 2021.

Acquisition and integration-related costs

Acquisition and integration-related costs for the year ended December 31, 2022
included costs for legal and advisory fees for the Mint and Lotus acquisition
that closed in October 2022 and the HireUp acquisition that closed in December
2022. Acquisition and integration-related costs for the year ended December 31,
2021 included costs for legal and advisory fees, as well as integration costs,
for the WSG acquisition that closed late in the second quarter of 2021, and
legal and professional fees for the Selected acquisition that closed late in the
fourth quarter of 2021.

Restructuring costs

Restructuring costs for the years ended December 31, 2022 and 2021 were
primarily comprised of employee termination costs and ongoing lease costs
related to the Company's strategic reduction of its real estate footprint and
totaled $1.9 million and $2.6 million, respectively. Amounts for the year ended
December 31, 2022 include a benefit associated with the early termination of the
lease for one of the Company's corporate offices in the second quarter, which
was previously restructured.

Impairment charges

Non-cash impairment charges totaled $5.6 million for the year ended December 31,
2022 and related to real estate restructuring activities and the write-off of a
discontinued IT project. Non-cash impairment charges totaled $2.1 million for
the year ended December 31, 2021 and related to real estate restructuring
activities and the write-off of a discontinued software development project. See
Note 5 - Goodwill, Trade Names, and Other Intangible Assets and Note 9 - Leases
to our consolidated financial statements.

Interest expense

Interest expense was $14.4 million for the year ended December 31, 2022 compared
to $6.9 million for the year ended December 31, 2021, due to higher average
borrowings and a higher effective interest rate. The effective interest rate on
our borrowings was 9.1% and 5.7% for the years ended December 31, 2022 and 2021,
respectively.

Loss on early extinguishment of debt

Loss on early extinguishment of debt for the year ended December 31, 2022
consisted of a prepayment premium and the write-off of debt issuance costs
related to the optional prepayments on our term loan made in the second and
fourth quarters of 2022. There were no such expenses for the year ended December
31, 2021.

Other income, net

For the year ended December 31, 2022, other income, net included a $1.1 million
gain on lease termination as a result of the early termination of one of our
corporate offices.

                                       28
--------------------------------------------------------------------------------

Income tax expense

Income tax expense totaled $67.9 million for the year ended December 31, 2022,
compared to $1.2 million for the year ended December 31, 2021. The effective tax
rate was 26.5% and 1.0%, including the impact of discrete items, for the years
ended December 31, 2022 and 2021, respectively. The effective tax rate in 2022
was impacted by federal, international, and state taxes. The effective tax rate
in 2021 was impacted by the release of valuation allowance on deferred tax
assets and federal, international, and state taxes.

For the year ended December 31, 2021, we recorded a net valuation allowance
release of $37.5 million (comprised of $18.4 million related to federal NOLs,
$7.5 million related to state NOLs, and $11.6 million related to other net
deferred tax assets) on the basis of management's reassessment of the amount of
its deferred tax assets that are more likely than not to be realized. The
valuation allowance on an immaterial amount of state NOLs was not released due
to the respective expiration periods and specific state taxable income
projections. See Note 13 - Income Taxes to our consolidated financial
statements.

Segment Results

Information on operating segments and a reconciliation to income from operations
for the periods indicated are as follows:

                                                        Year Ended December 31,
                                                         2022             2021
                                                        (amounts in thousands)

Revenues from services:

        Nurse and Allied Staffing                   $  2,700,383      $

1,605,781
        Physician Staffing                               106,226           70,871
                                                    $  2,806,609      $ 1,676,652

        Contribution income:

        Nurse and Allied Staffing                   $    355,447      $  

205,738
        Physician Staffing                                 5,508            4,328
                                                         360,955          210,066

        Corporate overhead                                67,087           55,142
        Depreciation and amortization                     12,576            

9,852

        Acquisition and integration-related costs            726            1,068
        Restructuring costs                                1,861            2,630

        Impairment charges                                 5,597            2,070

        Income from operations                      $    273,108      $  

139,304

In the first quarter of 2021, the Company modified its reportable segments and,
as a result, now discloses the following two reportable segments - Nurse and
Allied Staffing and Physician Staffing. See Note 17 - Segment Data.

Certain statistical data for our business segments for the periods indicated are
as follows:

                                                Year Ended December 31,                                     Percent
                                                2022                 2021              Change                Change

Nurse and Allied Staffing statistical
data:
FTEs                                             12,980              8,679               4,301                   49.6  %

Average Nurse and Allied Staffing revenue
per FTE per day                            $        565          $     503          $       62                   12.3  %

Physician Staffing statistical data:
Days filled                                      60,038             44,169              15,869                   35.9  %
Revenue per day filled                     $      1,769          $   1,605          $      164                   10.2  %

See definition of Business Measurements under the Operating Metrics section of
our Management's Discussion and Analysis.

                                       29
--------------------------------------------------------------------------------

Segment Comparison - Year Ended December 31, 2022 compared to the Year Ended
December 31, 2021

Nurse and Allied Staffing

Revenue increased $1.1 billion, or 68.2% to $2.7 billion for the year ended
December 31, 2022, from $1.6 billion for the year ended December 31, 2021,
through strong performance driven by volume increases and higher bill rates.

Contribution income for the year ended December 31, 2022, increased $149.7
million or 72.8%, to $355.4 million from $205.7 million for the year ended
December 31, 2021, driven by increased revenue. As a percentage of segment
revenue, contribution income margin increased to 13.2% for the year ended
December 31, 2022 from 12.8% for the year ended December 31, 2021.

The average number of FTEs on contract during the year ended December 31, 2022
increased 49.6% from the year ended December 31, 2021, primarily due to
headcount growth in travel nurse and allied, as well as additional headcount
resulting from the WSG acquisition. Average revenue per FTE per day increased
approximately 12.3% in the year ended December 31, 2022 compared to the year
ended December 31, 2021, due to the increase in the average travel bill rates.
Physician Staffing

Revenue increased $35.3 million, or 49.9% to $106.2 million for the year ended
December 31, 2022, compared to $70.9 million for the year ended December 31,
2021, primarily due to an increase in volume in several specialties.
Contribution income for the year ended December 31, 2022, increased $1.2 million
or 27.3% to $5.5 million compared to $4.3 million in the year ended December 31,
2021. As a percentage of segment revenue, contribution income was 5.2% for the
year ended December 31, 2022 and 6.1% for the year ended December 31, 2021,
driven by higher revenue, partially offset by higher direct costs.

Total days filled increased 35.9% to 60,038 in the year ended December 31, 2022,
compared to 44,169 in the year ended December 31, 2021. Revenue per day filled
was $1,769 for the year ended December 31, 2022 and $1,605 for the year ended
December 31, 2021.

Corporate overhead

Corporate overhead includes unallocated executive leadership and other
centralized corporate functional support costs such as finance, IT, legal, human
resources, and marketing, as well as public company expenses and corporate-wide
projects. Corporate overhead increased to $67.1 million for the year ended
December 31, 2022, from $55.1 million for the year ended December 31, 2021,
primarily due to increases in compensation and benefit expense, legal expense,
and computer expense. As a percentage of consolidated revenue, corporate
overhead was 2.4% for the year ended December 31, 2022, and 3.3% for the year
ended December 31, 2021.

Liquidity and Capital Resources

At December 31, 2022, we reported $3.6 million in cash and cash equivalents,
$73.9 million of term loan outstanding, at par, and $76.8 million of borrowings
drawn under our ABL. Working capital increased by $95.5 million to $404.0
million as of December 31, 2022, compared to $308.5 million as of December 31,
2021, primarily due to an increase in accounts receivable, partially offset by
the timing of disbursements. As of December 31, 2022, our days' sales
outstanding, net of amounts owed to subcontractors, was 72 days, up 14 days
year-over-year, primarily due to the timing of collections throughout the year.
As of December 31, 2022, we do not have any off-balance sheet arrangements.

Our operating cash flow constitutes our primary source of liquidity and,
historically, has been sufficient to fund our working capital, capital
expenditures, internal business expansion, and debt service. This includes our
commitments, both short-term and long-term, of interest expense on our debt and
operating lease commitments, and future principal payments on our term loan and
our ABL credit facility. We expect to meet our future needs from a combination
of cash on hand, operating cash flows, and funds available through the ABL. See
debt discussion which follows.

In the third quarter of 2022, our Board of Directors authorized the New
Repurchase Program, whereby we may repurchase up to $100.0 million of our shares
of common stock. Upon completion of the authorized number of shares available
for repurchase under the Prior Repurchase Program, we commenced repurchases
under the New Repurchase Program during the third quarter of 2022. During the
third and fourth quarters, we repurchased, under both the Prior Repurchase
Program and the New

                                       30
--------------------------------------------------------------------------------


Repurchase Program, a total of 1,364,815 shares of common stock for $35.3
million, at an average market price of $25.83 per share. As of December 31,
2022, we had $76.2 million remaining for share repurchase under the New
Repurchase Program, subject to certain conditions in our Loan Agreement and Term
Loan Agreement. During the fourth quarter of 2022, we entered into a Rule 10b5-1
Repurchase Plan to allow for share repurchases during our blackout periods.

Cash Flow Comparisons

Year Ended December 31, 2022 Compared to Year Ended December 31, 2021

Net cash provided by operating activities during the year ended December 31,
2022 was $134.1 million compared to net cash used in operating activities of
$85.6 million during the year ended December 31, 2021. The year over year
improvement in cash flow from operations was primarily due to the investments in
net working capital with higher accounts receivables stemming from the rapid
growth in the business in late 2021 into early 2022.

Net cash used in investing activities during the year ended December 31, 2022
was $43.9 million compared to $34.0 million in the year ended December 31, 2021.
Net cash used in the year ended December 31, 2022 included $35.1 million
primarily related to the acquisitions of Mint and HireUp, as well as capital
expenditures, primarily related to multiple IT projects. Net cash used for the
year ended December 31, 2021 included $26.9 million related to the acquisitions
of WSG and Selected, as well as capital expenditures and the build-out of our
corporate office.

Net cash used in financing activities for the year ended December 31, 2022 was
$87.6 million, compared to net cash provided by financing activities of $119.1
million during the year ended December 31, 2021. During the year ended December
31, 2022, we reported $67.6 million of net borrowings on our ABL and used cash
to repay borrowings of $100.4 million on our term loan, $2.4 million on our note
payable, $5.3 million for income taxes on share-based compensation, $3.2 million
in debt issuance costs, $35.3 million for share repurchases, $7.5 million for
contingent consideration, and $1.1 million for other financing activities.
During the year ended December 31, 2021, we reported net borrowings of $175.0
million on our term loan, and used cash to repay borrowing on our ABL of $44.2
million, $0.7 million principal payment on our term loan, $2.4 million on our
note payable, $6.1 million of debt issuance costs, $2.2 million for income taxes
on share-based compensation, and an immaterial amount for other financing
activities.

Debt

2021 Term Loan Agreement

As more fully described in Note 8 - Debt to our consolidated financial
statements, on June 8, 2021, we entered into a Term Loan Agreement, which
provides for a six-year second lien subordinated term loan in the amount of
$100.0 million (term loan). The term loan has an interest rate of one-month
LIBOR plus 5.75% per annum, subject to a 0.75% LIBOR floor. The term loan was
used to pay the cash consideration, as well as any costs, fees, and expenses in
connection with the WSG acquisition (see Note 4 - Acquisitions to our
consolidated financial statements), with the remainder used to pay down a
portion of the asset-based credit facility.

The borrowings under the Term Loan Agreement generally bear interest at a
variable rate based on either LIBOR or Base Rate (as defined in the Term Loan
Agreement) and are subject to mandatory prepayments of principal payable in
quarterly installments, commencing on September 30, 2021, with each installment
being in the aggregate principal amount of $0.3 million (subject to adjustment
as a result of prepayments) provided that, to the extent not previously paid,
the aggregate unpaid principal balance would be due and payable on the maturity
date. The Term Loan Agreement contains various restrictions and covenants
applicable to the Company and its subsidiaries, including a covenant to maintain
a minimum net leverage ratio. The Company was in compliance with this covenant
as of December 31, 2022. Obligations under the Term Loan Agreement are secured
by substantially all the assets of the borrowers and guarantors under the Term
Loan Agreement, subject to customary exceptions.

On November 18, 2021, we amended the Term Loan Agreement (Term Loan First
Amendment), which provided the Company an incremental term loan in an aggregate
amount equal to $75.0 million. Additionally, the Term Loan First Amendment
increased the aggregate amount of all increases (as defined in the Term Loan
Agreement) to be no greater than $115.0 million. The borrowings will be used
primarily to fund organic growth. Commencing on December 31, 2021, installments
of the mandatory prepayments will be in the aggregate principal amount of $0.4
million. All other terms, conditions, covenants, and pricing of the Term Loan
Agreement remain the same.

                                       31
--------------------------------------------------------------------------------


In addition to our scheduled payments, on June 23, 2022 and October 26, 2022, we
made optional prepayments of $50.0 million, totaling $100.0 million, to reduce
interest costs, and incurred prepayment premiums of $1.0 million pursuant to the
Term Loan Agreement. As a result of the early prepayments, debt issuance costs
of $1.4 million and $1.3 million were written off in the second and fourth
quarters of 2022, respectively. The prepayment premiums and the write-off of
debt issuance costs are included as loss on early extinguishment of debt in the
consolidated statements of operations and comprehensive income (loss).

In the first quarter of 2023, we expect to amend our Term Loan Agreement to
convert the LIBOR rates to SOFR rates.

2019 Loan Agreement

Effective October 25, 2019, our prior senior credit facility entered into in
August 2017 was replaced by a $120.0 million Loan Agreement, which provides for
a five-year senior secured revolving credit facility. On June 30, 2020, we
amended the Loan Agreement (First Amendment), which increased the current
aggregate committed size of the ABL from $120.0 million to $130.0 million. All
other terms, conditions, covenants, and pricing of the Loan Agreement remained
the same. On March 8, 2021, we amended the Loan Agreement (Second Amendment),
which increased the current aggregate committed size of the ABL from $130.0
million to $150.0 million, increased certain borrowing base sub-limits, and
decreased both the cash dominion event and financial reporting triggers. On June
8, 2021, we amended the Loan Agreement (Third Amendment), which permits the
incurrence of indebtedness and grant of security as set forth in the Loan
Agreement and in accordance with the Intercreditor Agreement, and provides
mechanics relating to a transition away from LIBOR as a benchmark interest rate
to a replacement alternative benchmark rate or mechanism for loans made in U.S.
dollars. On November 18, 2021, we amended the Loan Agreement (Fourth Amendment),
whereby the permitted indebtedness (as defined in the Loan Agreement) was
increased to $175.0 million. On March 21, 2022, we amended the Loan Agreement
(Fifth Amendment), which increased the current aggregate committed size of the
ABL from $150.0 million to $300.0 million, extended the credit facility for an
additional five years, increased certain borrowing base sub-limits, and provided
the option for all or a portion of the borrowings to bear interest at a rate
based on the Secured Overnight Financing Rate (SOFR) or Base Rate, at the
election of the borrowers, plus an applicable margin.

As of December 31, 2022, the interest rate spreads and fees under the Loan
Agreement were based on SOFR plus 1.85% for the revolving portion of the
borrowing base. The Base Rate (as defined by the Loan Agreement) margin would
have been 0.75% for the revolving portion. The SOFR and Base Rate margins are
subject to monthly pricing adjustments, pursuant to a pricing matrix based on
our excess availability under the revolving credit facility. In addition, the
facility is subject to an unused line fee, letter of credit fees, and an
administrative fee. The Loan Agreement contains various restrictions and
covenants, including a covenant to maintain a minimum fixed charge coverage
ratio. We were in compliance with the fixed charge coverage ratio covenant as of
December 31, 2022. Borrowing base availability under the ABL was $300.0 million
at December 31, 2022, with $76.8 million of borrowings drawn as well as $18.2
million of letters of credit outstanding, leaving $205.0 million of excess
availability.

Note Payable

The first two installments of $2.4 million each related to the subordinated
promissory note payable, made in connection with the New Mediscan II, LLC,
Mediscan Diagnostic Services, LLC, and Mediscan Nursing Staffing, LLC
(collectively Mediscan) acquisition, were paid in the second quarter of 2020 and
in the first quarter of 2021, respectively. The third and final installment of
$2.6 million, including interest of 2% per annum, accruing from April 1, 2020,
was paid in the first quarter of 2022. See Note 4 - Acquisitions.

See Note 8 - Debt to our consolidated financial statements.

Critical Accounting Policies and Estimates

We have identified the following critical accounting policies that affect the
more significant judgments and estimates used in the preparation of our
consolidated financial statements. The preparation of our consolidated financial
statements in conformity with accounting principles generally accepted in the
United States of America requires us to make estimates and judgments that affect
our reported amounts of assets and liabilities, revenues and expenses, and
related disclosures of contingent assets and liabilities. We evaluate our
estimates on an on-going basis, including those related to asset impairment,
accruals for self-insurance, allowance for doubtful accounts and sales
allowances, taxes and other contingencies, and litigation. We state our
accounting policies in the notes to the audited consolidated financial
statements for the year ended December 31, 2022, contained herein. These
estimates are based on information that is currently available to us and on
various assumptions that we
                                       32
--------------------------------------------------------------------------------

believe to be reasonable under the circumstances. Actual results could vary from
those estimates under different assumptions or conditions.

We believe that the following critical accounting policies affect the more
significant judgments and estimates used in the preparation of our consolidated
financial statements:

Goodwill, trade names, and other intangible assets

Our business acquisitions typically result in the recording of goodwill, trade
names, and other intangible assets, and the recorded values of those assets may
become impaired in the future. The determination of the value of such intangible
assets requires management to make estimates and assumptions that affect our
consolidated financial statements. For intangible assets purchased in a business
combination, the estimated fair values of the assets received are used to
establish their recorded values. As more fully described in Note 2 - Summary of
Significant Accounting Policies, we assess the impairment of goodwill of our
reporting units and indefinite-lived intangible assets annually, or more often
if events or changes in circumstances indicate that the carrying value may not
be recoverable.

Application of the goodwill impairment test requires judgment, including the
identification of reporting units, assignment of assets and liabilities to
reporting units, assignment of goodwill to reporting units, and determination of
the fair value of each reporting unit. Significant judgments are required to
estimate the fair value of reporting units including estimating future cash
flows, and determining appropriate discount rates, growth rates, company control
premium, and other assumptions. Changes in these estimates and assumptions could
materially affect the determination of fair value for each reporting unit. See
Note 5 - Goodwill, Trade Names, and Other Intangible Assets, where impairment
testing in 2022, 2021, and 2020 is more fully described.

Indefinite-lived intangible assets related to our trade names were not amortized
but instead tested for impairment at least annually, or more frequently should
an event or circumstances indicate that a reduction in fair value may have
occurred. We perform testing of indefinite-lived intangible assets, other than
goodwill, at the asset group level using the relief from royalty method. If the
carrying value exceeds the fair value, an impairment loss is recorded for that
excess.

There can be no assurance that the estimates and assumptions made for purposes
of the annual impairment test will prove to be accurate predictions of the
future. Although management believes the assumptions and estimates made are
reasonable and appropriate, different assumptions and estimates could materially
impact the reported financial results.

In addition, we are required to test the recoverability of long-lived assets,
including identifiable intangible assets with definite lives, whenever events or
changes in circumstances indicate that the carrying amount may not be
recoverable. In testing for potential impairment, if the carrying value of the
asset group exceeds the expected undiscounted cash flows, we must then determine
the amount by which the fair value of those assets exceeds the carrying value
and determine the amount of impairment, if any.

Risk and Uncertainties

The calculation of fair value used in these impairment assessments included a
number of estimates and assumptions that required significant judgments,
including projections of future income and cash flows, long-term growth rates,
the identification of appropriate market multiples, royalty rates, and the
choice of an appropriate discount rate. See Note 5 - Goodwill, Trade Names, and
Other Intangible Assets. In addition, deterioration of demand for our services,
deterioration of labor market conditions, reduction of our stock price for an
extended period, or other factors as described in Item 1A. Risk Factors, may
affect our determination of fair value of goodwill, trade names, or other
intangible assets. This evaluation can also be triggered by various indicators
of impairment which could cause the estimated discounted cash flows to be less
than the carrying amount of net assets. If we are required to record an
impairment charge in the future, it could have an adverse impact on our results
of operations. Under the current credit agreements, an impairment charge will
not have an impact on our liquidity. As of December 31, 2022, we had total
goodwill and other intangible assets of $208.0 million or 21.9% of our total
assets.

Health, workers' compensation, and professional liability expense

We maintain accruals for our health, workers' compensation, and professional
liability claims that are partially self-insured and are classified as accrued
compensation and benefits on our consolidated balance sheets. We determine the
adequacy of these accruals by periodically evaluating our historical experience
and trends related to health, workers' compensation, and professional liability
claims and payments, based on actuarial models, as well as industry experience
and trends. If such models indicate that our accruals are overstated or
understated, we will adjust accruals as appropriate. Healthcare insurance
accruals
                                       33
--------------------------------------------------------------------------------


have fluctuated with increases or decreases in the average number of corporate
employees and healthcare professionals on assignment as well as actual company
experience and increases in national healthcare costs. As of December 31, 2022
and 2021, we had $6.2 million and $4.1 million accrued, respectively, for
incurred but not reported health insurance claims. Corporate and field employees
are covered through a partially self-insured health plan. Workers' compensation
insurance accruals can fluctuate over time due to the number of employees and
inflation, as well as additional exposures arising from the current policy year.
As of December 31, 2022, and 2021, we had $14.9 million and $12.5 million
accrued for case reserves and for incurred but not reported workers'
compensation claims, net of insurance receivables, respectively. The accrual for
workers' compensation is based on an actuarial model which is prepared or
reviewed by an independent actuary quarterly. As of December 31, 2022, and 2021,
we had $4.2 million and $4.9 million accrued, respectively, for case reserves
and for incurred but not reported professional liability claims, net of
insurance receivables. The accrual for professional liability is based on
actuarial models which are prepared by an independent actuary quarterly.

Revenue recognition

We recognize revenue from our services when control of the promised services is
transferred to our customers, in an amount that reflects the consideration we
expect to receive in exchange for the service. We have concluded that transfer
of control of our staffing services, which represents the majority of our
revenues, occurs over time as the services are provided.

The following is a description of the nature, amount, timing and uncertainty of
revenue and cash flows from which we generate revenue.

Temporary Staffing Revenue

Revenue from temporary staffing is recognized as control of the services is
transferred over time, and is based on hours worked by our field staff. We
recognize the majority of our revenue at the contractual amount we have the
right to invoice for services completed to date. Generally, billing to customers
occurs weekly, bi-weekly, or monthly and is aligned with the payment of services
to the temporary staff. Accounts receivable includes estimated revenue for
employees' and independent contractors' time worked but not yet invoiced. At
December 31, 2022 and December 31, 2021, our estimate of amounts that had been
worked but had not been billed totaled $152.4 million and $140.0 million,
respectively, and are included in accounts receivable in the consolidated
balance sheets.

Other Services Revenue

We offer other services to our customers that are transferred over time
including: MSPs providing agency services (as further described below in Gross
Versus Net Policies), RPO, other outsourcing services, and retained search
services, as well as separately billable travel and housing costs, which in
total amount to less than 5% of our consolidated revenue for the years ended
December 31, 2022, 2021, and 2020. Generally, billing and payment terms for MSP
agency services are consistent with temporary staffing as the customers are
similar or the same. Revenue from these services is recognized based on the
contractual amount for services completed to date which best depicts the
transfer of control of services.

For our RPO, other outsourcing, and retained search services, revenue is
generally recognized in the amount to which the entity has a right to invoice
which corresponds directly with the value to the customer. We do not, in the
ordinary course of business, offer warranties or refunds.

Gross Versus Net Policies

We record revenue on a gross basis as a principal or on a net basis as an agent
depending on the contracted arrangement, as follows:

•We have certain contracts with acute care facilities to provide comprehensive
MSP solutions. Under these contract arrangements, we primarily use our nurses,
along with third-party subcontractors, to fulfill customer orders. If a
subcontractor is used, we invoice our customer for these services, but revenue
is recorded at the time of billing, net of any related subcontractor liability.
The resulting net revenue represents the administrative fee charged by us for
our MSP services.

•Revenue from our Physician Staffing business is recognized on a gross basis as
we are the principal in the arrangements.

                                       34
--------------------------------------------------------------------------------

Allowances

We maintain an allowance for doubtful accounts for estimated losses resulting
from the inability of our customers to make required payments, which results in
a provision for bad debt expense. We determine the adequacy of this allowance
based on historical write-off experience, current conditions, an analysis of the
aging of outstanding receivable and customer payment patterns, and specific
reserves for customers in adverse conditions adjusted for current expectations
for the customers or industry. Based on the information currently available, we
also considered current expectations of future economic conditions, including
the impact of the ongoing COVID pandemic, when estimating our allowance for
doubtful accounts. If the financial condition of our customers were to
deteriorate, resulting in an impairment of their ability to make payments,
additional allowances may be required. We write off specific accounts based on
an ongoing review of collectability as well as our past experience with the
customer. In addition, we maintain a sales allowance for rate and hour
differences which may arise in the ordinary course of business and adjustments
to the reserve are recorded as contra-revenue. As of December 31, 2022 and 2021,
our total allowances were $14.7 million and $6.9 million, respectively.

Contingent liabilities

We are subject to various litigation, claims, investigations, and other
proceedings that arise in the ordinary course of our business. These matters
primarily relate to employee-related matters that include individual and
collective claims, professional liability, tax, and payroll practices. Our
healthcare facility customers may also become subject to claims, governmental
inquiries and investigations, and legal actions to which we may become a party
relating to services provided by our professionals. We record a liability when
available information indicates that a loss is probable, and an amount or range
of loss can be reasonably estimated. Significant judgment is required to
determine both the probability of loss and the estimated amount. At least
quarterly, we review our accrual and/or disclosures to reflect the impact of
negotiations, settlements, rulings, advice of legal counsel, or new information.
However, losses ultimately incurred could materially differ from amounts
accrued. See Note 12 - Contingencies.

Income taxes

Deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between financial statement carrying
amounts of existing assets and liabilities and their respective tax bases and
operating loss and other loss carryforwards. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or
settled. During 2021, the Company fully utilized its federal NOL carryforward
and a significant amount of state NOLs. As of December 31, 2022, we have
deferred tax assets related to certain state and foreign NOL carryforwards of
$1.4 million. But for those NOL carryforwards with an indefinite carryover, the
carryforwards will expire as follows: state between 2023 and 2040, and foreign
between 2023 and 2027. As of December 31, 2021, we had deferred tax assets
related to certain state and foreign NOL carryforwards of $4.5 million.
As of December 31, 2022 and 2021, we had an immaterial amount of valuation
allowances on our deferred tax assets. For the year ended December 31, 2021, we
recorded a valuation allowance release of $37.5 million (comprised of $18.4
million related to federal NOLs, $7.5 million related to state NOLs, and $11.6
million related to other net deferred tax assets) on the basis of management's
reassessment of the amount of its deferred tax assets that are more likely than
not to be realized. For the year ended December 31, 2021, the valuation
allowance on an immaterial amount of state NOLs was not released due to the
respective expiration periods and specific state taxable income projections. See
Note 13 - Income Taxes to our consolidated financial statements.

As of each reporting date, management considers new evidence, both positive and
negative, that could affect its view of the future realization of deferred tax
assets. As of December 31, 2021, in part because for the 12 quarters ended
December 31, 2021, the Company had $110.3 million in cumulative pretax income
including permanent items. The Company also has a history of utilizing NOLs
prior to expiration, most notably the full utilization of the federal net
operating loss carryforward in 2021. The Company forecasts positive pretax book
income which is expected to exceed the reversal of its future tax deductions,
further proving future estimates of taxable income. Management determined that
there was sufficient positive evidence to conclude that it is more likely than
not that our net deferred tax assets are realizable. Growth estimates are tied
to the increasing demand for healthcare solutions for our customers, including
an aging U.S. population, and our customers' need to keep costs down by using
our staffing solutions. We therefore reduced the valuation allowance
accordingly.

With regard to negative evidence, the Company did not have any material taxable
temporary differences to offset deductible temporary differences and did not
have any taxable income available for carryback to offset NOLs. As such, the
primary focus
                                       35
--------------------------------------------------------------------------------

of our analysis emphasized the current and prior two-year cumulative pretax
income analysis, the full utilization of the federal net operating loss
carryforward, and projections of future taxable income.

We are subject to income taxes in the U.S. and certain foreign jurisdictions.
Significant judgment is required in determining our consolidated provision for
income taxes and recording the related deferred tax assets and liabilities. In
the ordinary course of our business there are many transactions and calculations
where the ultimate tax determination is uncertain. An unrecognized tax benefit
represents the difference between the recognition of benefits related to
exposure items for income tax reporting purposes and financial reporting
purposes. For the years ended December 31, 2022 and 2021, the unrecognized tax
benefit is included in uncertain tax positions - non-current in the consolidated
balance sheets. However, for the year ended December 31, 2021, $0.4 million of
the unrecognized tax benefit is classified as an offset to certain state NOLs
within the deferred tax asset. As of December 31, 2022, total unrecognized tax
benefits recorded was $7.6 million. We reserve for interest and penalties on
exposure items, if applicable, which is recorded as a component of the overall
income tax provision.

We are regularly under audit by tax authorities. Although the outcome of tax
audits is always uncertain, we believe that we have appropriate support for the
positions taken on our tax returns and that our annual tax provision includes
amounts sufficient to pay any assessments. Nonetheless, the amounts ultimately
paid, if any, upon resolution of the issues raised by the taxing authorities may
differ materially from the amounts accrued for each year.

Seasonality

See Item 1. Business.

Inflation

We do not believe that inflation had a significant impact on our results of
operations for the periods presented. On an ongoing basis, we seek to ensure
that billing rates reflect increases in costs due to inflation. In addition, we
attempt to minimize any residual impact on our operating results by controlling
operating costs.

Recent Accounting Pronouncements

See Note 2 - Summary of Significant Accounting Policies to our consolidated
financial statements.

Stockholders' Equity

See Note 14 - Stockholders' Equity to our consolidated financial statements.

Transactions with Related Parties

See Note 16 - Related Party Transactions to our consolidated financial
statements.